drugset / Trial / NCT00990704

Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism

NCT00990704

Phase 2 Completed 47 enrolled Abbott
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a exploratory comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in chronic kidney disease participants receiving hemodialysis with secondary hyperparathyroidism.

Timeline

Start
2009-10
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Paricalcitol Other / unclassified 2 ug Intravenous
Comparator maxacalcitol Small molecule 5 ug Intravenous
Comparator maxacalcitol Small molecule 10 ug Intravenous